Janux Therapeutics Inc (JANX)vsModerna Inc (MRNA)
JANX
Janux Therapeutics Inc
$16.93
-0.18%
HEALTHCARE · Cap: $1.01B
MRNA
Moderna Inc
$190.01
+0.57%
HEALTHCARE · Cap: $69.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 9183% more annual revenue ($2.23B vs $24.00M). JANX leads profitability with a 0.0% profit margin vs -141.4%. JANX earns a higher WallStSmart Score of 38/100 (F).
JANX
Hold38
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.7%
Fair Value
$116.25
Current Price
$16.93
$99.32 discount
Margin of Safety
+69.9%
Fair Value
$134.59
Current Price
$190.01
$55.42 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Revenue surging 2178.0% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 11.2x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : JANX
The strongest argument for JANX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 2178.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : JANX
The primary concerns for JANX are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
JANX profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
JANX carries more volatility with a beta of 2.52 — expect wider price swings.
JANX is growing revenue faster at 2178.0% — sustainability is the question.
JANX generates stronger free cash flow (-328,000), providing more financial flexibility.
Bottom Line
JANX scores higher overall (38/100 vs 21/100) and 2178.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Janux Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapies based on the patented Tumor Activated T Cell Engager (TRACTr) platform technology to treat cancer patients. The company is headquartered in La Jolla, California.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?